In:
Pediatric Blood & Cancer, Wiley, Vol. 70, No. 4 ( 2023-04)
Kurzfassung:
Patients with relapsed osteosarcoma have poor treatment outcomes. High‐dose chemotherapy with autologous stem cell transplantation (HDCT/ASCT) has been used in several high‐risk malignant solid tumors; however, few studies have evaluated their role in treating osteosarcoma. We evaluated the effectiveness of HDCT/ASCT in relapsed pediatric osteosarcoma cases. Procedure We retrospectively reviewed the medical records of 40 patients diagnosed with and treated for relapsed osteosarcoma at Asan Medical Center and Samsung Medical Center from January 1996 to July 2019. Results The median age of this cohort was 13.4 years (range: 6.1–18.2). The cohort's 5‐year overall survival (OS) was 51.0% ± 0.1% during a median follow‐up period of 67.5 months. Twenty‐five patients (62.5%) achieved complete remission (CR) with salvage treatment, and the 5‐year OS was 82.4% ± 0.1%, whereas none of the remaining 15 patients who did not achieve CR survived ( p 〈 .0001). Of the 25 CR cases, 15 underwent subsequent HDCT/ASCT. We compared the effect of HDCT/ASCT among patients who achieved CR. There were no significant differences in the 5‐year OS outcomes between patients who did and did not receive HDCT/ASCT (83.9% ± 0.1%, 13/15 vs. 80.0% ± 0.1%, 8/10, respectively; p = .923). Conclusion To our knowledge, we report the first comparative cohort study that proved HDCT/ASCT does not significantly improve survival outcomes in relapsed osteosarcoma. Achievement of CR remains the most crucial factor for good survival outcomes.
Materialart:
Online-Ressource
ISSN:
1545-5009
,
1545-5017
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2023
ZDB Id:
2130978-4
